Literature DB >> 16203926

Vascular endothelial growth factor is required for coronary collateral growth in the rat.

Eiji Toyota1, David C Warltier, Tommy Brock, Erik Ritman, Christopher Kolz, Peter O'Malley, Petra Rocic, Marta Focardi, William M Chilian.   

Abstract

BACKGROUND: The goal of this study was to determine whether the expression of vascular endothelial growth factor (VEGF) is critical for coronary collateral growth. Previous studies have provided an association between coronary collateral growth and VEGF, but none have allowed determination of a causal role. METHODS AND
RESULTS: We measured coronary collateral growth in rats subjected to repetitive episodes of myocardial ischemia (RI; one 40-second occlusion every 20 minutes for 2 hours 40 minutes, followed by 5 hours 20 minutes of rest, with this 8-hour cycle repeated 3 times per day for 10 days). Collateral growth was measured from blood flow (radioactive microspheres), visualization of arterial-arterial anastomoses (x-ray micro-CT), and maintenance of function during complete coronary occlusion in 3 groups of animals: sham (received instrumentation but no RI), experimental (subjected to RI), and anti-vascular endothelial growth factor (RI+anti-VEGF 0.6 mg/100 g per day) to block the endogenous actions of VEGF. In the 3 groups, native collateral flow (measurement for RI or sham protocol) averaged 0.2 to 0.3 mL x min(-1) x g(-1) of tissue. In the sham group, collateral flow did not increase during the protocol. Collateral flow in the control RI group increased by approximately 6-fold to 1.63 mL x min(-1) x g(-1) tissue, but in the anti-VEGF group, collateral flow did not increase after the RI protocol (0.22 mL x min(-1) x g(-1)). In acute experiments, collateral flow was unchanged during vasodilation with dipyridamole, indicating the increases in collateral flow are due to collateral growth and not vasodilation. X-ray micro-CT analysis revealed a 3-fold increase (versus sham group) in the number of arterial-arterial anastomoses per heart after RI, which was prevented by treatment with anti-VEGF. The growth of the collateral circulation was functional in the RI group because complete coronary occlusion did not induce any untoward effects on hemodynamics or arrhythmias. In the sham or anti-VEGF groups, coronary occlusion at the end of the protocol induced many arrhythmias and deterioration of function.
CONCLUSIONS: From these results, we conclude that the expression of VEGF is critical to the growth of coronary collaterals.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16203926     DOI: 10.1161/CIRCULATIONAHA.104.526954

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  62 in total

1.  Retrograde perfusion and filling of mouse coronary vasculature as preparation for micro computed tomography imaging.

Authors:  Jill J Weyers; Dara D Carlson; Charles E Murry; Stephen M Schwartz; William M Mahoney
Journal:  J Vis Exp       Date:  2012-02-10       Impact factor: 1.355

2.  Differential Expression of Vascular Endothelial Growth Factor-A165 Isoforms Between Intracranial Atherosclerosis and Moyamoya Disease.

Authors:  Hao Jiang; Juan F Toscano; Michael Schiraldi; Shlee S Song; Konrad H Schlick; Oana M Dumitrascu; Raymond Liou; Patrick D Lyden; Jianwei Pan; Renya Zhan; Jeffrey L Saver; Nestor R Gonzalez
Journal:  J Stroke Cerebrovasc Dis       Date:  2018-11-02       Impact factor: 2.136

Review 3.  Redox-dependent mechanisms in coronary collateral growth: the "redox window" hypothesis.

Authors:  June Yun; Petra Rocic; Yuh Fen Pung; Souad Belmadani; Ana Catarina Ribeiro Carrao; Vahagn Ohanyan; William M Chilian
Journal:  Antioxid Redox Signal       Date:  2009-08       Impact factor: 8.401

Review 4.  The role of mitochondrial bioenergetics and reactive oxygen species in coronary collateral growth.

Authors:  Yuh Fen Pung; Wai Johnn Sam; James P Hardwick; Liya Yin; Vahagn Ohanyan; Suzanna Logan; Lola Di Vincenzo; William M Chilian
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-08-30       Impact factor: 4.733

5.  Inhibition of protein tyrosine phosphatases enhances cerebral collateral growth in rats.

Authors:  Ivo Buschmann; Daniel Hackbusch; Nora Gatzke; André Dülsner; Manuela Trappiel; Markus Dagnell; Arne Ostman; Rob Hooft van Huijsduijnen; Kai Kappert
Journal:  J Mol Med (Berl)       Date:  2014-05-27       Impact factor: 4.599

6.  State-of-the-Art Methods for Evaluation of Angiogenesis and Tissue Vascularization: A Scientific Statement From the American Heart Association.

Authors:  Michael Simons; Kari Alitalo; Brian H Annex; Hellmut G Augustin; Craig Beam; Bradford C Berk; Tatiana Byzova; Peter Carmeliet; William Chilian; John P Cooke; George E Davis; Anne Eichmann; M Luisa Iruela-Arispe; Eli Keshet; Albert J Sinusas; Christiana Ruhrberg; Y Joseph Woo; Stefanie Dimmeler
Journal:  Circ Res       Date:  2015-04-30       Impact factor: 17.367

7.  Vascular endothelial growth factor-A specifies formation of native collaterals and regulates collateral growth in ischemia.

Authors:  Jason A Clayton; Dan Chalothorn; James E Faber
Journal:  Circ Res       Date:  2008-09-18       Impact factor: 17.367

8.  MMPs 2 and 9 are essential for coronary collateral growth and are prominently regulated by p38 MAPK.

Authors:  Tracy Dodd; Rashmi Jadhav; Luke Wiggins; James Stewart; Erika Smith; James C Russell; Petra Rocic
Journal:  J Mol Cell Cardiol       Date:  2011-08-22       Impact factor: 5.000

9.  Skeletal myofiber VEGF is essential for the exercise training response in adult mice.

Authors:  Hamid Delavar; Leonardo Nogueira; Peter D Wagner; Michael C Hogan; Daniel Metzger; Ellen C Breen
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2014-02-12       Impact factor: 3.619

10.  Endothelial nuclear factor-κB-dependent regulation of arteriogenesis and branching.

Authors:  Daniela Tirziu; Irina M Jaba; Pengchun Yu; Bruno Larrivée; Brian G Coon; Brunella Cristofaro; Zhen W Zhuang; Anthony A Lanahan; Martin A Schwartz; Anne Eichmann; Michael Simons
Journal:  Circulation       Date:  2012-10-22       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.